Investors with the goal of beating the broader market often turn to stock selection. Strategic choices in individual stocks can have a profound impact on your wealth.
After finishing at $81.12 in the prior trading day, Corcept Therapeutics Inc (NASDAQ: CORT) closed at $82.28, up 1.43%. In other words, the price has increased by $1.43 from its previous closing price. On the day, 1.09 million shares were traded. CORT stock price reached its highest trading level at $82.98 during the session, while it also had its lowest trading level at $79.02.
Ratios:
Our goal is to gain a better understanding of CORT by taking a closer look at its different ratios. It provided that stocks Price–to–Cash (P/C) ratio for the trailing twelve months (TTM) is standing at 20.52 whereas its Price-to-Free Cash Flow (P/FCF) for the term is 53.24. For the most recent quarter (mrq), Quick Ratio is recorded 3.07 and its Current Ratio is at 3.14. In the meantime, Its Debt-to-Equity ratio is 0.01 whereas as Long-Term Debt/Eq ratio is at 0.01.
Truist Upgraded its Hold to Buy on November 06, 2023, whereas the target price for the stock was revised from $29 to $38.
Insider Transactions:
The insider trade also gives investors a glimpse into the future direction of stock prices, which can be beneficial to investors. A recent insider transaction in this stock occurred on Dec 02 ’25 when Guyer William sold 20,000 shares for $80.08 per share. The transaction valued at 1,601,526 led to the insider holds 1,235 shares of the business.
Maduck Sean sold 20,000 shares of CORT for $1,590,490 on Dec 01 ’25. The insider now owns 7,904 shares after completing the transaction at $79.52 per share. On Dec 01 ’25, another insider, Lyon Joseph Douglas, who serves as the insider of the company, sold 5,000 shares for $79.53 each. As a result, the insider received 397,632 and left with 10,277 shares of the company.
Valuation Measures:
Investors should consider key stock statistics when deciding whether to invest or divest. In the wake of the recent closing price, CORT now has a Market Capitalization of 8669985792 and an Enterprise Value of 8239561728. As of this moment, Corcept’s Price-to-Earnings (P/E) ratio for their current fiscal year is 94.01, and their Forward P/E ratio for the next fiscal year is 67.50. The expected Price-to-Earnings-to-Growth (PEG) calculation for the next 5 years is 1.32. For the stock, the TTM Price-to-Sale (P/S) ratio is 11.68 while its Price-to-Book (P/B) ratio in mrq is 13.69. Its current Enterprise Value per Revenue stands at 11.117 whereas that against EBITDA is 123.508.
Stock Price History:
The Beta on a monthly basis for CORT is 0.17, which has changed by 0.5859238 over the last 52 weeks, in comparison to a change of 0.15905356 over the same period for the S&P500. Over the past 52 weeks, CORT has reached a high of $117.33, while it has fallen to a 52-week low of $49.00. The 50-Day Moving Average of the stock is 5.34%, while the 200-Day Moving Average is calculated to be 12.70%.
Shares Statistics:
The stock has traded on average 883.73K shares per day over the past 3-months and 1033330 shares per day over the last 10 days, according to various share statistics. A total of 105.12M shares are outstanding, with a floating share count of 93.21M. Insiders hold about 11.39% of the company’s shares, while institutions hold 74.69% stake in the company. Shares short for CORT as of 1764288000 were 10341891 with a Short Ratio of 11.70, compared to 1761868800 on 11046701. Therefore, it implies a Short% of Shares Outstanding of 10341891 and a Short% of Float of 13.29.
Earnings Estimates
Currently, 6.0 analysts are dedicated to thoroughly evaluating and rating the performance of Corcept Therapeutics Inc (CORT) in the stock market.The consensus estimate for the next quarter is $0.09, with high estimates of $0.51 and low estimates of -$0.45.
Analysts are recommending an EPS of between $1.18 and $0.81 for the fiscal current year, implying an average EPS of $0.97. EPS for the following year is $1.34, with 6.0 analysts recommending between $2.84 and -$0.74.
Revenue Estimates
5 analysts predict $261.13M in revenue for. The current quarter. It ranges from a high estimate of $272.4M to a low estimate of $248.59M. As of. The current estimate, Corcept Therapeutics Inc’s year-ago sales were $181.89MFor the next quarter, 5 analysts are estimating revenue of $238.19M. There is a high estimate of $300M for the next quarter, whereas the lowest estimate is $210M.
A total of 5 analysts have provided revenue estimates for CORT’s current fiscal year. The highest revenue estimate was $831.7M, while the lowest revenue estimate was $807.9M, resulting in an average revenue estimate of $820.4M. In the same quarter a year ago, actual revenue was $675.04MBased on 5 analysts’ estimates, the company’s revenue will be $1.18B in the next fiscal year. The high estimate is $1.39B and the low estimate is $1.01B.
